Earnings Release • Sep 13, 2023
Earnings Release
Open in ViewerOpens in native device viewer
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il The Food (+32.8%) and Pharma (+34.9%) BUs drive the Group's growth. Fine Foods' margins show a significant recovery compared to H1 2022.
vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime Verdellino (Bergamo, Italy), 13 September 2023 - The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. - an Italian independent Contract Development & Manufacturing Organisation (CDMO) that develops and manufactures contract products for the pharmaceutical, nutraceutical, and cosmetics industries, listed on Euronext STAR Milan (ticker: FF), today approved the Half-Year Financial Report as of 30 June 2023.
***
Name Surname H1 2023 showed Consolidated Revenues of € 127.5 million, up 26.7% compared to € 100.6 million in H1 2022.
Role Company Revenues of the Food Business Unit in H1 2023 were € 75.4 million with a growth of 32.8% compared to € 56.8 million in H1 2022.
The Pharma Business Unit contributed to the growth in H1 2023, rising from € 25.8 million in H1 2022 to € 34.8 million in H1 2023 (+34.9%).
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. The Cosmetic Business Unit contribution in the first six months of 2023 was € 17.2 million compared to € 18 million recorded in the same period of 2022. This decrease was also generated by the disposal of some nonstrategic business lines.
facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Fine Foods & Pharmaceuticals N.T.M. S.p.A. Chief Executive Officer Giorgio Ferraris, said: "The first half of 2023 closed with significantly higher revenues (+26.7%) compared to the same period of 2022 driven by our Food and Pharma BUs, which have almost completely overcome the difficulties arising from the international economic and geopolitical trends. The Cosmetic BU performance reflected the impact of the reorganisation which should be completed by the end of 2023. The positive performance of H1 is confirmed by a substantial order portfolio, which confirms a more than positive outlook for H2."
simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. The Group's H1 2023 EBITDA was € 12.6 million compared to € 7.8 million in the first half of 2022, showing a growth of +61%. EBITDA for H1 2023 coincided with the Adjusted EBITDA which was € 8.4 million in H1 2022.
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin The Group's H1 2023 EBITDA Margin, which coincided with the Adjusted EBITDA Margin, was 9.9%, with a significant improvement from 7.8% in 2022. The H1 2022 Adjusted EBITDA Margin was 8.3%.
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus The margin improvement derived from the reduction in the impact of personnel and energy costs on revenues, and better absorption of fixed costs on revenues. The energy percentage cost is still higher than the historical cost. This impact is estimated at almost 0.6% on EBITDA, equal to about € 0.8 million, which would have brought EBITDA to € 13.4 million, with a margin of 10.5%.
plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro The Operating result (EBIT) for H1 2023 was € 0.4 million and showed a slight decrease compared to H1 2022 generated mainly by the goodwill impairment of Pharmatek (merged into Euro Cosmetic), of € 4.4 million. Without this effect, EBIT would have been € 4.8 million. This impairment was part of the broader reorganisation of the Cosmetic Business Unit, which included the disposal of some non-strategic business lines. H1 2023 EBIT was affected by the above energy impact, net of which it would have been € 1.3 million, € 5.7 million net of the above impairment.
velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. The Income Before Taxes for H1 2023 was € -0.1 million compared to € -5.9 million in H1 2022. This result was almost entirely attributable to the impairment of Pharmatek's goodwill which merged by incorporation into Euro Cosmetic.
endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit This led to a loss in H1 2023 of € 1.7 million (€ -6 million in H1 2022). The adjusted result for H1 2023, net of the goodwill impairment, was € 2.7 million compared to the adjusted loss for the period of € 5.6 million as of 30 June 2022.
harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. The result for both periods was impacted by changes in the Fair Value of financial assets. In H1 2023, the Parent Company's asset securities management showed a positive change in Fair Value of € 1.7 million. The
Name Surname Role Company trend contrasted the corresponding period of the previous year (negative change in Fair Value of € 5.8 million). As of 30 June 2023, the Company closed its position with the primary Credit Institution which was entrusted with the management service for its investment portfolio in January 2019. The overall portfolio management, from the opening to closure, was positive for € 5.7 million.
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Tangible Fixed Assets increased by approximately € 1.6 million in H1 2023, due to net investments of € 8 million and depreciation for the period of € 6.4 million.
eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Intangible fixed assets and rights of use were € 17.1 million as of 30 June 2023 (€ 22.8 million at the end of FY 2022). This decrease was mainly due to the Pharmatek's goodwill impairment of € 4.4 million.
Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Working capital as of 30 June 2023 was € 58.7 million compared to € 44.2 million at the end of the previous financial year. The Commercial Net Working Capital, of € 62 million (compared to € 46.3 million as of 31 December 2022), changed as follows: increase in trade receivables (€ 9.5 million), inventories (€ 10.9 million) and trade payables (€ 4.7 million).
solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur Shareholders' Equity as of 30 June 2023 was € 129.1 million, up from 31 December 2022 (€ 133.3 million).
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic The Group's Net Financial Position as of 30 June 2023 was € 57.8 million, compared to the NFP of € 43.6 million as of 31 December 2022. The change was mainly due to the absorption of the Commercial Net Working Capital, CAPEX made in the period and distribution of FY 2022 dividends.
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. No significant events occurred after the end of the period.
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same The global economy is recovering after the difficult period generated by the Covid-19 pandemic and the recent geopolitical events. However, global economic activity is impacted by high inflation and restrictive financing conditions. The energy cost, although lower than in the previous period, remains significantly higher than historical trends.
nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma The Group will develop the business along three main lines - Food, Pharma, and Cosmetics - by strengthening corporate functions' activities. Fine Foods will seize any opportunities for growth through external lines.
conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea The increase in turnover recorded in the first half of the year confirmed the effectiveness of the commercial actions taken for the Food BU and allowed us to forecast a largely positive outlook.
vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia The Pharma BU is expected to significantly grow due to the key multi-year agreements signed with important international customers that will require a production plant expansion.
con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid The integration and optimisation of processes will continue for the Cosmetic BU. Investments for the Trenzano site production capacity expansion are nearing completion. Efficiency is expected to improve when fully operational and customer demand is expected to increase. The Cremosano plant was permanently closed and production transferred to Trenzano.
earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. The second quarter showed a decrease in margin compared to the first quarter which was mainly attributable to the Cosmetic BU reorganisation activities. Despite this, management remains reasonably confident of the margin improvement trend, in view of the results achieved in the period after the end of the half-year.
Name Surname Role Company The Groups believes in a fair and sustainable future, creating long-term value for the benefit of its stakeholders and contributing to the development and well-being of the communities in which it operates. Fine Foods has been a benefit corporation since April 2021. ESG issues for Fine Foods are a structured set of activities and the Group intends to continue its sustainability programme in the future.
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a It should be noted that under Article 154-ter, paragraph 2, of Legislative Decree no. 58 of 24 February 1998, the Half-year financial report as of 30 June 2023, approved by the Board of Directors on today's date, will be made available today to shareholders and the public at the registered office, on the Company's website at www.finefoods.it, Investor Relations/Financial Reports section, and the authorised storage system .
***
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat Under Art. 154-bis, paragraph 2 of the Consolidated Law on Financial Intermediation, the Manager responsible for preparing the corporate financial reports, Pietro Bassani, declared that the accounting information contained in this press release corresponds to the document results, accounting books and records.
simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.
Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin
***
archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent CDMO (Contract Development and Manufacturing Organisation) It develops and manufactures contract products for the pharmaceutical, nutraceutical and cosmetics industries. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, long-term partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. With € 207 million revenue in 2022 and more than 10 per cent CAGR over the last decade, Fine Foods is a growing and future-oriented company.
id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit For further information: Fine Foods & Pharmaceuticals N.T.M. S.p.A. Tel +39 035 4821382 Investor Relations: [email protected] Media Relations: [email protected]
| Company | ||||
|---|---|---|---|---|
| (amounts in € units) | Notes | Half-year as of | Half-year as of | |
| 30 June 2023 | 30 June 2022 | |||
| Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Revenues and income |
||||
| eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Revenues from contracts with customers |
2.1 | 127,460,518 | 100,579,641 | |
| invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Other revenues and income |
2.2 | 1,108,891 | 232,668 | |
| Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Total revenues |
128,569,409 | 100,812,309 | ||
| maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum | ||||
| Operating costs facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore |
||||
| Costs for consumption of raw materials, change in inventories of solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a |
79,184,580 | 60,551,439 | ||
| finished goods and work in progress. dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet |
2.3 | dercill itiatem cum que doluptur | ||
| Personnel costs | 2.4 | 22,571,196 | 19,629,655 | |
| magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi Costs for services |
2.5 | 13,212,226 | 12,067,688 | |
| ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Other operating costs |
2.6 | 984,846 | 725,352 | |
| estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Amortisation, depreciation, and impairment losses |
2.7 | 12,168,816 | 7,298,070 | |
| ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Total operating costs |
128,121,664 | tem etum laborat 100,272,205 |
||
| estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Operating result |
447,745 | 540,104 | ||
| simus. | ||||
| Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Changes in fair value of financial assets and liabilities |
2.8 | 1,702,536 | (5,845,820) | |
| Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Financial income |
2.9 | 32,367 | 7,728 | |
| Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin Financial charges |
2.10 | (2,290,377) | (595,628) | |
| cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Income before taxes |
(107,729) | (5,893,615) | ||
| archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Income taxes |
2.11 | 1,555,543 | 142,183 | |
| offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet Profit/(loss) for the financial year |
(1,663,272) | (6,035,798) |
| nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma (amounts in € units) conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea |
Half-year as of 30 June 2023 |
Half-year as of 30 June 2022 |
|
|---|---|---|---|
| iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea Profit /(loss) for the financial year (A) vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro |
Note s |
(1,663,272) | (6,035,798) |
| velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia Components that will not be subsequently reclassified to con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil profit/(loss) for the financial year id moluptatur. |
|||
| Revaluation of net employee benefit liabilities/assets | (28,741) | 324,505 | |
| endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime Tax effect eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid |
6,898 | (40,099) | |
| earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis Other comprehensive income (B) components dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit |
(21,843) | 284,406 | |
| harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. | |||
| Comprehensive profit/(loss) (A+B) | (1,685,115) | (5,751,392) |
| Company | |||
|---|---|---|---|
| (amounts in € units) | Notes | 30 June 2023 | as of 31/12/2022 |
| Assets | |||
| Non-current assets Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil |
|||
| Property, plant and machinery | 3.1 | 105,763,602 | 104,162,050 |
| eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Goodwill |
3.2 | 11,507,954 | 15,907,954 |
| invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Other intangible fixed assets |
3.3 | 1,805,112 | 1,780,551 |
| Rights of use Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero |
3.4 | 3,790,372 | 5,163,111 |
| Other non-current assets | 3.7 | 354,120 | 820,871 |
| maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Deferred tax assets |
3.5 | 7,324,358 | 7,312,662 |
| facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Total non-current assets |
130,545,518 | 135,147,200 | |
| Current assets solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a |
|||
| Inventories | 3.8 | 51,283,098 | 40,422,499 |
| dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Trade receivables |
3.9 | 48,824,877 | dercill itiatem cum que doluptur 39,347,321 |
| magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi Tax receivables |
3.10 | 243,859 | 2,268,044 |
| Other current assets | 3.11 | 7,880,625 | 5,890,398 |
| ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Current financial assets |
3.12 | 3,844,715 | 66,512,584 |
| estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Cash and other liquid assets |
3.13 | 49,243,212 | 10,232,262 |
| ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Total current assets |
161,320,386 | tem etum laborat 164,673,109 |
|
| estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Total assets |
291,865,904 | 299,820,309 | |
| simus. | |||
| Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Shareholders' equity |
|||
| Share Capital | 4.1 | 22,770,445 | 22,770,445 |
| Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Other reserves |
4.1 | 114,419,640 | 126,461,456 |
| Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin Employee benefit reserve |
4.1 | 184,343 | 206,186 |
| FTA reserve cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea |
4.1 | (6,669,789) | (6,669,789) |
| Profits carried forward | 4.1 | 22,610 | 22,610 |
| archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Profit/(loss) for the financial year |
4.1 | (1,663,272) | (9,501,145) |
| offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet Total Shareholders' Equity |
129,063,976 | 133,289,763 | |
| haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus | |||
| Non-current liabilities | |||
| plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Bonds |
4.2 | - | - |
| Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same Non-current bank borrowings |
4.3 | 70,079,730 | 77,573,797 |
| Employee benefits nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma |
4.5 | 2,311,693 | 2,419,013 |
| Provision for risks and charges | 4.6 | 36,305 | 41,105 |
| conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea Provision for deferred taxes |
3.6 | 248,757 | 240,553 |
| iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea Non-current lease payables |
3.4 | 1,271,003 | 2,222,216 |
| Total non-current liabilities vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro |
73,947,488 | 82,496,684 | |
| velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia Current liabilities |
|||
| con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil Bonds |
4.2 | 3,329,404 | 3,323,051 |
| Current bank borrowings | 4.4 | 35,871,031 | 36,590,346 |
| id moluptatur. Trade payables |
4.7 | 38,121,073 | 33,450,468 |
| endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime Taxes payable |
4.8 | 159,014 | - |
| eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid Current lease payables |
3.4 | 380,421 | 651,576 |
| Other current liabilities | 4.9 | 10,993,497 | 10,018,421 |
| earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis Total current liabilities |
88,854,440 | 84,033,862 | |
| dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit | |||
| harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Total Shareholders' equity and Liabilities |
291,865,904 | 299,820,309 |
| Role Company |
Half-year as of 30 June 2023 |
Half-year as of 30 June 2022 |
||
|---|---|---|---|---|
| PROFIT/(LOSS) FOR THE FINANCIAL YEAR | (1,663,272) | (6,035,798) | ||
| Adjustments to reconcile profit after tax with net cash flows: | ||||
| Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Depreciation and impairment of property, plant and machinery 2.7 |
6,821,818 | 6,382,993 | ||
| eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Amortisation and impairment of intangible fixed assets 2.7 |
411,551 | 443,964 | ||
| Amortisation of rights of use 2.7 invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. |
535,446 | 471,112 | ||
| Other write-downs of fixed assets 2.7 |
4,400,000 | - | ||
| Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Financial income 2.9 |
(32,367) | (7,728) | ||
| maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Financial charges 2.10 |
2,290,888 | 568,076 | ||
| facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Changes in fair value of financial assets and liabilities 2.8 |
(1,702,536) | 5,845,820 | ||
| Financial charges on financial liabilities for leases 3.4 solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a |
(512) | 27,552 | ||
| Income taxes 2.11 |
1,552,408 | (27,953) | ||
| dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Personnel costs for stock grants 2.4 |
dercill itiatem cum que doluptur - |
- | ||
| magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi Gains on the disposal of property, plant and machinery 2.2 |
(21,888) | (37,826) | ||
| ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Current assets write-downs 3.8,3.9 |
497,988 | 662,594 | ||
| Net change in severance indemnity and pension funds 4.5 estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic |
(174,114) | (203,827) | ||
| Net change in provision for risks and charges 4.6 |
(4,800) | 260,345 | ||
| ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Net change in deferred tax assets and liabilities 3.5,3.6 |
3,135 | tem etum laborat 177,915 |
||
| estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Interest paid 2.10 |
(2,219,685) | (575,006) | ||
| Income taxes paid 2.11 simus. |
- | - | ||
| Changes in net working capital: Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. |
||||
| (Increase)/decrease in inventories 3.8 |
(11,128,342) | (7,991,340) | ||
| Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? (Increase)/decrease in trade receivables 3.9 |
(9,750,142) | (12,507,781) | ||
| Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin (Increase)/decrease in other non-financial assets and liabilities |
92,733 | 4,428,328 | ||
| cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Disposal of assets held for sale |
- | - | ||
| Increase/(decrease) in trade payables 4.7 archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo |
4,702,605 | 898,346 | ||
| NET CASH FLOWS FROM OPERATING ACTIVITIES | (5,389,086) | (7,220,212) | ||
| offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet | ||||
| haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus Investments: |
||||
| plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Investments in tangible fixed assets 3.1 |
(8,761,356) | (8,198,109) | ||
| Disposal of tangible fixed assets 3.1 Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same |
359,874 | 105,590 | ||
| Investments in intangible fixed assets 3.3 |
(436,112) | (450,078) | ||
| nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma Net (investments)/disposals in financial assets 3.12 |
52,370,405 | 258,874 | ||
| conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea Acquisition of Subsidiaries 3.2 |
- | - | ||
| iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea NET CASH FLOWS FROM INVESTMENTS |
43,532,810 | (8,283,723) | ||
| vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro | ||||
| Financing: velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia |
||||
| New financing 4.3,4.4 |
27,284,521 | 71,680,229 | ||
| con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil Funding repayment 4.2,4.3,4.4 |
(23,491,549) | (47,453,448) | ||
| id moluptatur. Principal payments - lease liabilities 3.4 |
(385,075) | (541,321) | ||
| Dividends paid to the parent company's shareholders 4.1 endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime |
(2,452,708) | (3,866,869) | ||
| Share capital increase 4.1 eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid |
- | - | ||
| Sale/(purchase) of treasury shares 4.1 |
(87,963) | (748,815) | ||
| earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis CASH FLOWS FROM FINANCING |
867,225 | 19,069,776 | ||
| dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit NET CHANGE IN CASH AND CASH EQUIVALENTS |
39,010,949 | 3,565,841 | ||
| harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Cash and short-term deposits as of 1 January |
10,232,262 | 17,118,957 | ||
| Cash and short-term deposits as of 30 June | 49,243,212 | 20,684,799 |
Fine Foods & Pharmaceuticals N.T.M. S.p.A. Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]
| Company Mus. Optas et |
Notes maximus |
Share Capital il , tem |
Legal reserve ium et |
Negative reserve for treasury shares in the portfolio a nestorem |
Merger surplus reserve acese laudisi |
Share premium reserve tatur, |
Extraordinary reserve aut que eost |
Other reserves hil |
FTA reserve |
Employee benefit reserve |
Profits/losses carried forward |
Profit/loss for the financial year |
Total Shareholders' equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| eatiur doluptur aut rest, |
volorpo | rehenem | . Itati | volut | eaque estiist | pediscipsum | il mil ipsam |
il | |||||
| Balance as of 1 January 2023 invenducilla esse pra con pliquun |
4.1 | 22,770,445 tiatur , te |
5,000,000 volorer |
(13,680,454) ovidund |
29,741,389 electium |
86,743,750 resciat |
14,240,490 | 4,416,281 | (6,669,789) | 206,186 | 22,610 | (9,501,145) | 133,289,763 |
| Atiosa autatem Profit/(loss) for the financial year maio harum qui . Temperum Other income statement components |
poribus to |
ellaccum conem a abor |
, sum secto sunt, |
vellatiam odi atureic |
, utaturiorum temo |
esciaspedis | am, quat quaspero quiassum |
eum | (21,843) | (1,663,272) | (1,663,272) (21,843) |
||
| facitas mi , sint , ommoluptatur Comprehensive profit/(loss) |
pernatiist aut |
fugia | quidene | modioriatium | facepudis | ommolore ut |
(21,843) | - (1,663,272) | (1,685,115) | ||||
| solupta quiducilles erspis dolenimilit lam as volo quid Dividends magnihi odi voluptia ciurit IRS derivatives provision |
venimol | magnam ium et eossincium , ut |
ad earchit labo ecaesen delesen |
atioremqui . Ehendicat officet desciae |
dercill caborit |
hit arum sunt itiatem enimetureped |
, qui sin nost cum que doluptur (2,452,708) quidel |
a modi |
(2,452,708) - |
||||
| ut que sumquam, tem aut Purchase of treasury shares abo alis . Ut estrumetur 2022 profit allocation am dolupid ipiciet quia |
ipsum eum as et digent |
nonem est esti sit fugias eostia |
lit harum ut |
inihita mo qui (87,963) eum aut nossecus, invero |
nobis eaquis is od essit i , |
enturibusam repti cust officeni tem |
velent abore omnihic ni (9,501,145) etum |
quam laborat |
(9,501,145) | (87,963) - |
|||
| Balance as of 30 June 2023 quodic iuntest estrum tet |
4.1 | 22,770,445 , quo omnimus |
5,000,000 reptas |
(13,768,417) eosapitiis dolupta |
29,741,389 tecullam |
86,743,750 eum, od |
2,286,638 modipissunt |
4,416,281 , |
(6,669,789) | 184,343 | 22,610 | (1,663,272) | 129,063,977 |
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same Fine Foods & Pharmaceuticals N.T.M. S.p.A. Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.